A detailed history of Larson Financial Group LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Larson Financial Group LLC holds 30 shares of NTLA stock, worth $293. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Previous 62 51.61%
Holding current value
$293
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 07, 2025

SELL
$11.41 - $21.09 $365 - $674
-32 Reduced 51.61%
30 $0
Q3 2024

Nov 12, 2024

SELL
$19.72 - $27.36 $2,721 - $3,775
-138 Reduced 69.0%
62 $1,000
Q2 2024

Aug 02, 2024

BUY
$20.02 - $27.22 $3,403 - $4,627
170 Added 566.67%
200 $4,000
Q1 2024

May 03, 2024

BUY
$23.82 - $32.8 $476 - $656
20 Added 200.0%
30 $0
Q4 2023

Feb 01, 2024

BUY
$23.16 - $32.34 $231 - $323
10 New
10 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $744M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Larson Financial Group LLC Portfolio

Follow Larson Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Larson Financial Group LLC with notifications on news.